Status:
RECRUITING
A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients
Lead Sponsor:
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Conditions:
Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This is an open, multicenter Phase II clinical study of SSGJ-707 combined with chemotherapy in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer. The objecti...
Eligibility Criteria
Inclusion
- Age:18-75 years old
- Advanced endometrial cancer and platinum-resistant ovarian cancer
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Expected survival \>=12 weeks.
- Signed informed consent form.
Exclusion
- Known uncontrolled or symptomatic central nervous system metastatic disease.
- Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade \>1 (National Cancer Institute Common terminology Criteria \[NCI CTCAE\] v.5.0).
- Inadequate organ or bone marrow function.
- Pregnant or breast-feeding woman.
- Known allergies, hypersensitivity, or intolerance to SSGJ-707 The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Key Trial Info
Start Date :
October 10 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2026
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06522828
Start Date
October 10 2024
End Date
August 1 2026
Last Update
October 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chongqing Cancer Hospital
Chongqing, China